ADAR antibody (AA 367-471) (FITC)

Catalog No. ABIN7380667

Product Details anti-ADAR Antibody (FITC)

Target: ADAR (Adenosine Deaminase, RNA-Specific (ADAR))

Binding Specificity: AA 367-471

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This ADAR antibody is conjugated to FITC

Application: Please inquire

Cross-Reactivity: Human

Purification: >95%, Protein G purified

Immunogen: Recombinant Human Double-stranded RNA-specific adenosine deaminase protein (367-471AA)

Isotype: IgG

Application Details

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for ADAR

Target: ADAR (Adenosine Deaminase, RNA-Specific (ADAR))

Alternative Name: ADAR (ADAR Products)

Synonyms: red1 antibody, drada antibody, wu:fc22a02 antibody, adar1 antibody, dsRAD antibody, dsRAD-1 antibody, ADAR antibody, ADAR1 antibody, CG12598 antibody, Dmel\\CG12598 antibody, EG:BACN35H14.1 antibody, adar antibody, adr antibody, cg12598 antibody, dADAR antibody, dAdar antibody, hypnos-2 antibody, NV18763 antibody, AGS6 antibody, DRADA antibody, DSH antibody, DSRAD antibody, G1P1 antibody, IFI-4 antibody, IFI4 antibody, K88DSRBP antibody, P136 antibody, AV242451 antibody, Adar1 antibody, mZaADAR antibody, adenosine deaminase, RNA-specific antibody, adenosine deaminase, RNA-specific S homeolog antibody, adenosine deaminase, RNA specific antibody, Adenosine deaminase acting on RNA antibody, adenosine deaminase acting on RNA antibody, double-stranded RNA-specific editase 1 antibody, adar antibody, adar.S antibody, ADAR antibody, Adar antibody, CpipJ_CPIJ011849 antibody, LOC100114127 antibody

Background:

Background: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins, pre-mRNA splicing by altering splice site recognition sequences, RNA stability by changing sequences involved in nuclease recognition, genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication, and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5\'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication.

Aliases: 136 kDa double-stranded RNA-binding protein antibody, 136 kDa double stranded RNA binding protein antibody, Adar 1 antibody, ADAR antibody, Adar1 antibody, Adenosine deaminase acting on RNA 1 A antibody, Adenosine deaminase RNA specific 1 antibody, Adenosine deaminase RNA specific antibody, Adenosine deaminase that act on RNA antibody, AGS6 antibody, AV242451 antibody, Double stranded RNA specific adenosine deaminase antibody, Double-stranded RNA-specific adenosine deaminase antibody, Double-stranded RNA-specific editase Adar antibody, DRADA antibody, Dsh antibody, Dsrad antibody, DSRAD_HUMAN antibody, dsRNA adenosine deaminase antibody, EC 3.5.4.- antibody, G1P1 antibody, IFI 4 antibody, IFI-4 antibody, IFI4 antibody, Ifi4 protein antibody, Interferon induced protein 4 antibody, Interferon inducible protein 4 antibody, Interferon-inducible protein 4 antibody, K88DSRBP antibody, mZaADAR antibody, P136 antibody, Pre-mRNA adenosine deaminase antibody, RNA adenosine deaminase 1 antibody, RNA-editing deaminase 1 antibody, RNA-editing enzyme 1 antibody

UniProt: P55265

Pathways: Protein targeting to Nucleus